Trial Profile
Clinical Trials Insight: 700018793
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 Nov 2006
Price :
$35
*
At a glance
- Drugs Sapacitabine (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Cyclacel Pharmaceuticals
- 22 Nov 2006 18th EORTC-NCI-AACR Symposium
- 21 Nov 2006 New trial record.